ATF4-Mediated Metabolic Stress Response as a Therapeutic Vulnerability in Chordoma
Cottone, L.; Dunford, J. P.; Calcutt, E.; Gamble, V.; Aksu, F. S.; Ligammari, L.; Gaeta, G.; Christianson, J. C.; Flanagan, A. M.; Oppermann, U.; Cribbs, A. P.
Show abstract
Chordoma, a rare primary bone malignancy, currently lacks effective targeted therapies. Despite surgical resection and adjuvant radiotherapy, prognosis remains poor. Recent preclinical studies have highlighted potential therapeutic targets, including the transcription factor TBXT. However, clinical outcomes associated with therapies targeting TBXT remain underexplored or have been modest, warranting further investigation. In this study, we investigated the therapeutic potential of tRNA synthetase inhibitors in chordoma treatment. Focused compound screening identified distinct chemotypes targeting human glutamyl-prolyl-tRNA synthetase (EPRS) as effective in reducing cell viability in chordoma cell lines through an ATF4-mediated stress response rather than through TBXT regulation. Mechanistically significant upregulation of ATF4 and associated stress response genes was identified with consecutive pro-apoptotic DDIT3-mediated cell death. The prototypic EPRS inhibitor halofuginone demonstrated significant tumour growth inhibition in an in vivo patient-derived xenograft model. These results suggest that targeting metabolic stress pathways via ATF4 activation presents a novel therapeutic approach for chordoma, warranting further clinical investigation.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors 96%
- Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 95%
- Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer 94%
Similar papers in this journal
- Rapid Resistance To Bet Inhibitors Is Mediated By Fgfr1 In Glioblastoma 96%
- Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A 95%
- Collateral Responses to Classical Cytotoxic Chemotherapies are Heterogeneous and Sensitivities are Sparse 95%
Similar papers in this journal
- Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting 96%
- Sequential ATR and PARP Inhibition Overcomes Acquired DNA Damaging Agent Resistance in Pancreatic Ductal Adenocarcinoma 95%
- Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer 95%
Similar papers in this journal
- Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials 95%
- Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma 94%
- High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in SHH-medulloblastoma 94%
Similar papers in this journal
- Evaluation of KRASG12C Inhibitor Responses in Novel Murine KRASG12C Lung Cancer Cell Line Models 94%
- Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in GBM 94%
- Increased efficacy of histone methyltransferase G9a inhibitors against MYCN-amplified Neuroblastoma 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.